Announcement • May 02
Kodiak Sciences Presents Pipeline Advances and KSI-101 Clinical Data At Scientific Conferences
Kodiak Sciences Inc. announced it will present pipeline advances and clinical results of KSI-101 in a cohort of tertiary care MESI patients at the 2026 American Uveitis Society (AUS) Meeting and the 2026 Association for Research in Vision and Ophthalmology (ARVO) Meeting. Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia. Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies. The ABCD PlatformTM, an evolution of Kodiak's ABC platform to include conjugation of small molecules and other drugs, continues to advance as a versatile system for targeted, multi-modal drug development in retina and glaucoma optic neuropathy. Presentations at American Uveitis Society –Saturday, May 2, 2026, in Aurora, Colorado: Format: Oral presentation. Presentation Title: Bispecific Trap-antibody Inhibiting Interleukin-6 and Vascular Endothelial Growth Factor (KSI-101): Week 24 Results from the Phase 1b APEX Study in Patients with Macular Edema Secondary to Inflammation (MESI). Speaker: Dr. Edmund Tsui, M.D., Associate Professor-in-Residence of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles (UCLA), USA. Time:7:45pm MT. Presentations at Association for Research in Vision and Ophthalmology – May 3-7, 2026, in Denver, Colorado. Kodiak will have six poster presentations. Presentations are listed below and grouped by topic. These presentations will be made available under Kodiak's "Scientific Presentations" page on kodiak.com. Phase 1b APEX Data of KSI-101 in MESI, Including New Data from a Tertiary Care Cohort. KSI-101 is a first-in-class, locally administered, high-strength bispecific protein in clinical development for the treatment of MESI, a heterogeneous group of diseases caused by a common pathophysiology – inflammation and blood-retinal barrier disruption. In the Phase 1b APEX study conducted in the United States, KSI-101 demonstrated rapid and meaningful visual and anatomical gains and was well tolerated. KSI-101 was further evaluated in an Asian clinical cohort. Results from this cohort were consistent with those observed in the U.S., supporting continued global development and expansion into Asia for the Phase 3 MESI program PEAK and PINNACLE. At this year's ARVO meeting, we will present results from both the U.S. study and, for the first time, results from the Asian cohort. Title: Bispecific Trap-Antibody Inhibiting Interleukin-6 and Vascular Endothelial Growth Factor (KSI-101): Clinical PK/PD Cohort in Asian Patients with Macular Edema Secondary to Inflammation (MESI). Poster Session: Clinical features and treatment outcomes in uveitis. Date and Time: Monday, May 4, 11:15-1:00pm MT. Poster Number: 1568-0229. Speaker: Dr. Yih-Shiou Hwang, M.D., Ph.D., Professor and Head of Ophthalmology, Chang Gung Memorial Hospital, Linkou, Taipei and Taoyuan, Taiwan and Chang Gung University. We will present first-time results from a clinical cohort of Asian patients with MESI treated at tertiary uveitis centers in Taiwan. Patients achieved meaningful visual improvements, including a =15-letter gain in 58% of patients and a mean BCVA increase of +17.8 letters at Week 24. Central subfield thickness (CST) was reduced to.
